Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
NCT07085039Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in idiopathic multicentric Castleman disease (iMCD), sponsored by University of Pennsylvania. Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on NCT07085039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085039.